Voyager Therapeutics
VYGR
135 hedge funds and large institutions have $129M invested in Voyager Therapeutics in 2026 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 46 increasing their positions, 36 reducing their positions, and 17 closing their positions.
399% more call options, than puts
Call options by funds: $954K | Put options by funds: $191K
65% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 17
28% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 36
8% more funds holding
Funds holding: 125 → 135 (+10)
2% less capital invested
Capital invested by funds: $133M → $129M (-$3.24M)
4.45% less ownership
Funds ownership: 60.69% → 56.24% (-4.4%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$6.09M |
| 2 |
VPC
Vestal Point Capital
New York
|
+$6.02M |
| 3 |
DP
Diadema Partners
Morristown,
New Jersey
|
+$1.67M |
| 4 |
Two Sigma Investments
New York
|
+$1.55M |
| 5 |
Renaissance Technologies
New York
|
+$1.11M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$15.7M |
| 2 |
AC
Armistice Capital
New York
|
-$1.97M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.59M |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$823K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$756K |
VYGR Hedge Fund Activity: Q1 2026 in Review
135 institutional investors reported a position in Voyager Therapeutics (VYGR) for Q1 2026, worth a combined $129M — down 2.4% from $133M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new VYGR positions and 17 closed out — a net gain of 11 holders — while 46 added to existing stakes and 36 trimmed.
The largest buyer was Millennium Management, adding an estimated $6.09M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $15.7M sold.
- 135 institutional investors held Voyager Therapeutics (VYGR) as of Q1 2026, up from 125 in Q4 2025.
- Funds reported $129M of Voyager Therapeutics stock for Q1 2026, down 2.4% quarter-over-quarter.
- 28 funds opened new Voyager Therapeutics positions in Q1 2026 and 17 closed out, a net change of +11 holders.
- The largest Voyager Therapeutics buyer in Q1 2026 was Millennium Management, an estimated $6.09M added.
- The largest Voyager Therapeutics seller in Q1 2026 was EcoR1 Capital, an estimated $15.7M sold.
Based on aggregated 13F filings for Q1 2026.